
Lymphoma
Latest News

Latest Videos
Shorts
Podcasts
CME Content
More News

Patients with nodal TFHL had a 5.3% 5-year incidence of subsequent myeloid neoplasms, with shared TET2 mutations supporting divergent evolution from underlying clonal hematopoiesis.

Findings from EPCORE DLBCL-4 show that fixed-duration epcoritamab plus lenalidomide significantly improved progression-free survival (PFS) vs R-GemOx in relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Minimal residual disease (MRD) negativity exceeded 90% with 100% response and no progression in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Fixed-duration pirtobrutinib plus venetoclax-rituximab reduced the risk of progression or death by 45% and achieved higher undetectable MRD rates than venetoclax-rituximab alone.

Data presented at EHA 2026 showed that epcoritamab significantly improved progression-free survival and complete response rates compared with standard chemoimmunotherapy in patients with relapsed or refractory (RR) large B-cell lymphoma (LBCL).

Real‑world study finds grade 1 CRS during CD20 bispecific therapy for follicular lymphoma is often safe at home, reducing hospital use.

Phase 3 frontMIND phase 3 trial data show tafasitamab plus lenalidomide with R-CHOP boosts PFS and has manageable safety in high-risk newly diagnosed DLBCL.

Time to next treatment (TTNT) is an emerging real-world end point in CAR T-cell therapy that reflects treatment durability, clinical outcomes, and health care system factors beyond traditional efficacy measures.

Infection following CAR T-cell therapy is a common and clinically significant complication driven by prolonged immune dysregulation, cytopenias, and hypogammaglobulinemia, requiring phase-based risk awareness and proactive preventive management across the treatment continuum.

ASCO 2026: Glofitamab monotherapy shows durable remissions in relapsed mantle cell lymphoma after BTKi, with manageable CRS.

Data from a phase 1/2 trial revealed that CRISPR–Cas9–edited donor stem cell transplants lacking CD33 enabled rapid engraftment and allowed posttransplant gemtuzumab ozogamicin maintenance in high-risk patients with AML/MDS without prolonged hematologic toxicity.

FDA approves sonrotoclax for patients who have received at least 2 lines of systemic therapy, including a Bruton tyrosine kinase inhibitor.

Bispecific antibodies show strong efficacy in relapsed/refractory lymphoma and early promise in frontline combination settings.

COA 2026 reveals how bispecific antibodies transform lymphoma care—outpatient workflows, SOPs, and infection vigilance shape safe BTCE delivery.

The cellular FLICE-like inhibitory protein (cFLIP) is a critical regulator of extrinsic apoptosis and essential driver of diffuse large B-cell lymphoma pathogenesis.

EPCORE trial data show epcoritamab plus lenalidomide and rituximab delivers responses in relapsed/refractory follicular lymphoma with outpatient dosing.

FDA approves nivolumab with AVD for stage III/IV classical Hodgkin lymphoma, boosting PFS and redefining first-line care.

Ipsen discontinues tazemetostat after SYMPHONY-1 safety signals; pharmacists and FDA guide next steps for EZH2-mutant follicular lymphoma patients.

Frontline therapy for DLBCL is evolving with the integration of targeted and cellular therapies, demonstrating promising outcomes.

The epcoritamab, rituximab, and lenalidomide regimen provides a chemo-free, outpatient option for relapsed or refractory follicular lymphoma (FL), offering high response rates, improved quality of life, and expanding pharmacists’ roles in patient management.


















































































































